Peringatan Keamanan

No experience of overdosage from clinical trials.

Goserelin

DB00014

small molecule approved

Deskripsi

Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Struktur Molekul 2D

Berat 1269.4105
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 4-5 hours
Volume Distribusi * 44.1 ± 13.6 L [subcutaneous administration of 250 mcg]
Klirens (Clearance) * 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]

Absorpsi

Inactive orally, rapidly absorbed following subcutaneous administration.

Metabolisme

Hepatic

Rute Eliminasi

Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.

Interaksi Obat

1134 Data
Corifollitropin alfa The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Goserelin.
Ivabradine Ivabradine may increase the QTc-prolonging activities of Goserelin.
Choline C 11 Goserelin may decrease effectiveness of Choline C 11 as a diagnostic agent.
Capromab pendetide Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Goserelin.
Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Goserelin.
Insulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Goserelin.
Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Goserelin.
Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Goserelin.
Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin.
Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Goserelin.
Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Goserelin.
Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin.
Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin.
Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Goserelin.
Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.
Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Goserelin.
Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin.
Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin.
Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Goserelin.
Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin.
Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin.
Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin.
Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin.
Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin.
Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Goserelin.
Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin.
Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Goserelin.
Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Goserelin.
Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Goserelin.
Mecasermin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Goserelin.
Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Goserelin.
Glisoxepide The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Goserelin.
Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Goserelin.
Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Goserelin.
Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Goserelin.
Glymidine The therapeutic efficacy of Glymidine can be decreased when used in combination with Goserelin.
AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Goserelin.
Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Goserelin.
Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin.
Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Goserelin.
NN344 The therapeutic efficacy of NN344 can be decreased when used in combination with Goserelin.
AMG-222 The therapeutic efficacy of AMG-222 can be decreased when used in combination with Goserelin.
Bisegliptin The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Goserelin.
Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.
Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Goserelin.
Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin.
Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Goserelin.
Gosogliptin The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Goserelin.
Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.
Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.
Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Goserelin.
Benfluorex The therapeutic efficacy of Benfluorex can be decreased when used in combination with Goserelin.
Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.
Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Goserelin.
Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Goserelin.
Lobeglitazone The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Goserelin.
Netoglitazone The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Goserelin.
Rivoglitazone The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Goserelin.
Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Goserelin.
Lixisenatide The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Goserelin.
Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Goserelin.
Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Goserelin.
Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Goserelin.
Insulin tregopil The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Goserelin.
Ipragliflozin The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Goserelin.
Dutogliptin The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Goserelin.
Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Goserelin.
Tofogliflozin The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Goserelin.
Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Goserelin.
2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Goserelin.
Teneligliptin The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Goserelin.
Omarigliptin The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Goserelin.
Carmegliptin The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Goserelin.
Gemigliptin The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Goserelin.
Anagliptin The therapeutic efficacy of Anagliptin can be decreased when used in combination with Goserelin.
Evogliptin The therapeutic efficacy of Evogliptin can be decreased when used in combination with Goserelin.
Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Goserelin.
Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Goserelin.
Remogliflozin etabonate The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Goserelin.
Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Goserelin.
Guar gum The therapeutic efficacy of Guar gum can be decreased when used in combination with Goserelin.
Metahexamide The therapeutic efficacy of Metahexamide can be decreased when used in combination with Goserelin.
Semaglutide The therapeutic efficacy of Semaglutide can be decreased when used in combination with Goserelin.
Taspoglutide The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Goserelin.
Englitazone The therapeutic efficacy of Englitazone can be decreased when used in combination with Goserelin.
Tirzepatide The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Goserelin.
Gastric inhibitory polypeptide The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Goserelin.
Dofetilide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dofetilide.
Citalopram The risk or severity of QTc prolongation can be increased when Goserelin is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Goserelin is combined with Valproic acid.
Terfenadine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terfenadine.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Grepafloxacin.
Quinine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinine.
Sotalol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sotalol.
Erlotinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erlotinib.

Target Protein

Lutropin-choriogonadotropic hormone receptor LHCGR
Progonadoliberin-1 GNRH1
Gonadotropin-releasing hormone receptor GNRHR

Referensi & Sumber

Synthesis reference: Kripa S. Srivastava, Matthew R. Davis, "Solid Phase Peptide for the Production of Goserelin." U.S. Patent US20100311946, issued December 09, 2010.

Contoh Produk & Brand

Produk: 8 • International brands: 0
Produk
  • Zoladex
    Implant • 3.6 mg/1 • Subcutaneous • US • Approved
  • Zoladex
    Implant • 10.8 mg/1 • Subcutaneous • US • Approved
  • Zoladex
    Implant • 3.6 mg/1 • Subcutaneous • US • Approved
  • Zoladex
    Implant • 10.8 mg/1 • Subcutaneous • US • Approved
  • Zoladex
    Implant • 3.6 mg/1 • Subcutaneous • US • Approved
  • Zoladex
    Implant • 3.6 mg/1 • Subcutaneous • US • Approved
  • Zoladex
    Implant • 3.6 mg • Subcutaneous • Canada • Approved
  • Zoladex LA
    Implant • 10.8 mg • Subcutaneous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul